Australia's most trusted
source of pharma news
Posted 21 January 2022 PM
Competition in the MET inhibitor space for non-small cell lung cancer (NSCLC) is heating up in Australia with Merck's Tepmetko finally provisionally approved this week as Novartis closes in with its candidate.
The TGA has granted Tepmetko provisional approval for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.